The effect of oral medium chain triglycerides in healthy individuals

The effect of oral medium chain triglycerides in healthy individuals - Effect of oral MCT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46931

Enrollment

Registered

2017-10-13

Start date

2018-03-15

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

but a follow-up study will include Very Long Chain Acetyl-CoA Dehydrogenase deficiency (a fatty acid oxidation disorder) In this study only healthy subjects

Interventions

Medium-chain triglyceride emulsion (liquigen®), tracer: glycerol-tri(octanoate-1,2,3,4-13C4)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Healthy male - Age 18+ - BMI 18-25 kg/m2

Exclusion criteria

Exclusion criteria: Dyslipidemia (hypertriglyceridemia) Any acute or chronic illness that would interfere with the subjects safety and ability to comply with protocol requirements

Design outcomes

Primary

Measure	Time frame
Actual study: - 13C enrichment of breath CO2. - 13C enrichment of C12-22 of plasma fatty acids in plasma: triglycerides (TG), phospholipids (PL), Cholesterol esters (CE), VLDL, LDL, HDL and free fatty acids (FA) Pilot: * Establish minimum duration of fasting that enables us to detect appropriate levels of LCT and free fatty acids in plasma. * Establish duration of oral MCT administration to accurately measure enrichment in plasma fatty acids and breath CO2. * Establish if one week of wash-out period is sufficient to clear MCT-tracer from plasma.	—

Measure

Time frame

Actual study: - 13C enrichment of breath CO2. - 13C enrichment of C12-22 of plasma fatty acids in plasma: triglycerides (TG), phospholipids (PL), Cholesterol esters (CE), VLDL, LDL, HDL and free fatty acids (FA) Pilot: * Establish minimum duration of fasting that enables us to detect appropriate levels of LCT and free fatty acids in plasma. * Establish duration of oral MCT administration to accurately measure enrichment in plasma fatty acids and breath CO2. * Establish if one week of wash-out period is sufficient to clear MCT-tracer from plasma.

—

Secondary

Measure	Time frame
* Resting energy expenditure Pilot * Response of plasma metabolites (glucose, pyruvate, lactate, ketones, triglycerides, free fatty acids, insulin, cortisol, acylcarnitines, amino acids) to 36 hours of fasting	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)